MedTrace Logo

Congenital Athymia Patient Registry

NCT05329935 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 75

Last updated 2025-08-19

No results posted yet for this study

Summary

This Congenital Athymia Patient Registry is an observational exposure-based registry study. It uses a prospective cohort design to follow patients who have been treated with RETHYMIC.

Clinical studies conducted with investigational RETHYMIC showed that treatment can result in immune reconstitution and prolong life. This treatment-based registry is being conducted to learn more about the reconstitution process following treatment and the impact of treatment on longer-term survival and the occurrence of adverse events of special interest (AESI).

Conditions

  • Complete DiGeorge Anomaly
  • Complete DiGeorge Syndrome
  • Congenital Athymia

Interventions

BIOLOGICAL

Cultured Thymus Tissue

Product will be surgically administered into the quadriceps

Sponsors & Collaborators

  • Sumitomo Pharma Switzerland GmbH

    lead INDUSTRY

Eligibility

Min Age
0 Years
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-05-25
Primary Completion
2026-04-30
Completion
2026-04-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05329935 on ClinicalTrials.gov